Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma. LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -6.00p -5.08% 112.00p 17,026 09:48:15
Bid Price Offer Price High Price Low Price Open Price
111.00p 113.00p 118.00p 112.00p 118.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 48.79

Destiny Pharma. (DEST) Latest News (1)

More Destiny Pharma. News
Destiny Pharma. Takeover Rumours

Destiny Pharma. (DEST) Share Charts

1 Year Destiny Pharma. Chart

1 Year Destiny Pharma. Chart

1 Month Destiny Pharma. Chart

1 Month Destiny Pharma. Chart

Intraday Destiny Pharma. Chart

Intraday Destiny Pharma. Chart

Destiny Pharma. (DEST) Discussions and Chat

Destiny Pharma. Forums and Chat

Date Time Title Posts
30/12/201710:39Destiny Pharma plc27

Add a New Thread

Destiny Pharma. (DEST) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Destiny Pharma. trades in real-time

Destiny Pharma. (DEST) Top Chat Posts

Destiny Pharma. Daily Update: Destiny Pharma. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma. was 118p.
Destiny Pharma. has a 4 week average price of 112p and a 12 week average price of 112p.
The 1 year high share price is 254.50p while the 1 year low share price is currently 112p.
There are currently 43,562,598 shares in issue and the average daily traded volume is 3,181 shares. The market capitalisation of Destiny Pharma. is £48,790,109.76.
jonwig: At the risk of being a boor, I'll repeat my post #7 from four weeks ago: I saw the initial RNS and looked at the website. Basically their compounds appear to act so quickly that bacteria have no time to develop resistance via mutation. My immediate reaction to this was extreme scepticism. It appears to suggest that antibiotic resistant mutations happen when bacteria are stimulated by exposure to an agent. But this isn't the case: they happen purely randomly. Indeed there will already exist resistant strains, and resistant populations will develop and increase by natural selection as happens with current antibiotics. I met a biochemist last week (on holiday) whose discipline is immunology, so not quite the same, and he confirmed that my general understanding was correct. Obviously I need to do more study on this and it would be good to see if the company's research has been peer-reviewed. (A lot of these companies don't allow that.) I know their early trials have been successful, and I may be off-beam here, but I wouldn't want to invest in anything I didn't understand. I just can't find any corroborative information about their compounds (Help anyone?), and first results should be some time away. (How much?) Until then, it's unlikely the share price will do more than respond to speculative froth. A trigger will be phase results, and it's unlikely these can leak as they should be double-blind and reported immediately. When they are, how many here will understand them? More to the point, they seem to have £14m cash with a burn of £2m pa (but that will increase). At least they won't have to scramble.
Destiny Pharma. share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180322 15:59:00